| 21 |
|
Editorial board/
|
|
C. V. Mosby Co
|
2003
|
|
|
|
| 22 |
|
Editorial board/
|
|
C.V. Mosby Co
|
1900
|
|
|
|
| 23 |
|
Editorial board/
|
|
C. V. Mosby Co
|
2003
|
|
|
|
| 24 |
|
Editorial Board/
|
|
C. V. Mosby Co
|
2003
|
|
|
|
| 25 |
|
Editorial board/
|
|
C. V. Mosby Co
|
2003
|
|
|
|
| 26 |
|
Editorial board page/
|
|
C.V. Mosby Co
|
1900
|
|
|
|
| 27 |
|
Editorial board page/
|
|
C.V. Mosby Co
|
1900
|
|
|
|
| 28 |
|
Editorial comment: The short esophagus: Going, going, gone?/
|
DeMeester, S. R
|
C. V. Mosby Co
|
2003
|
|
|
|
| 29 |
|
Editorial - Postoperative atrial fibrillation after heart surgery: What are the goals of prevention?/
|
Kim, Michael H
|
C. V. Mosby Co
|
2001
|
|
|
|
| 30 |
|
Editorials - Aldosterone inhibition and heart failure: Too good to be true?/
|
Francis, Gary S
|
C. V. Mosby Co
|
2001
|
|
|
|
| 31 |
|
Editorials - And the beat goes on/
|
O'Rourke, Robert A
|
C. V. Mosby Co
|
2001
|
|
|
|
| 32 |
|
Editorials - Angiotensin-converting enzyme inhibitor dosing in heart failure: What is optimal?/
|
Gattis, Wendy A
|
C. V. Mosby Co
|
2001
|
|
|
|
| 33 |
|
Editorials - Aortic counterpulsation in acute myocardial infarction: Physiologically important but does the patient benefit?/
|
Ohman, E Magnus
|
C. V. Mosby Co
|
2001
|
|
|
|
| 34 |
|
Editorials - A second look at bivalirudin/
|
Antman, Elliott M
|
C. V. Mosby Co
|
2001
|
|
|
|
| 35 |
|
Editorials - Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure/
|
Felker, G Michael
|
C. V. Mosby Co
|
2001
|
|
|
|
| 36 |
|
Editorials - Biventricular pacing for congestive heart failure: Questions of who, what, where, why, how, and how much/
|
Kay, G Neal
|
C. V. Mosby Co
|
2001
|
|
|
|
| 37 |
|
Editorials - Cardiac enzyme elevations after cardiac surgery: The cardiologist's perspective/
|
Mahaffey, Kenneth W
|
C. V. Mosby Co
|
2001
|
|
|
|
| 38 |
|
Editorials - Cardiac marker testing: Where should we focus?/
|
Newby, L Kristin
|
C. V. Mosby Co
|
2000
|
|
|
|
| 39 |
|
Editorials - Clopidogrel instead of ticlopidine after coronary stent placement: Is the switch justified?/
|
Berger, Peter B
|
C. V. Mosby Co
|
2000
|
|
|
|
| 40 |
|
Editorial - Selecting end points in clinical trials: What evidence do we really need to evaluate a new treatment?/
|
Spertus, John
|
C. V. Mosby Co
|
2001
|
|
|
|